TrialInternational journal of hematology2018

Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.

Shinsuke Noguchi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.